Treatment effects of familact Probiotic in Non Alcoholic Fatty Liver Disease(NAFLD)

Phase 2

• Conditions: onalcoholic steatohepatitis.; Other specified inflammatory liver diseases, Nonalcoholic steatohepatitis [NASH]

• Registration Number: IRCT2014112019554N2
• Lead Sponsor: Zanjan University of Medical Sciences, Deputy of Research and Technology, Research Management

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

patients with NAFLD on ultrasonography; ALT more than 1.5 to 5 times the normal range; BMI between 25 to 29.9
Exclusion criteria: alcoholic hepatitis; systemic or metabolic or inflammatory disease such as diabetes; viral hepatitis; autoimmune hepatitis; secondary fatty liver disease such as drug induced fatty liver disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood pressure. Timepoint: at the first and after 8 weeks. Method of measurement: Manometer.;Body mass index. Timepoint: at the first and after 8 weeks. Method of measurement: Analog scale, Meter.;Fasting blood glucose. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.;Total cholestrol. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.;LDL. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.;HDL?. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.;TG. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.;AST. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.;ALT. Timepoint: at the first and after 8 weeks. Method of measurement: ELISA.